Author: Aldiyarbek Nurlan
Editor: Merentsova Anastasia
The research team has previously demonstrated how remdesivir inhibits polymerase or the replication mechanism of the COVID-19 virus in vitro (in vitro).
Remdesivir stops or severely delays the replication of the virus, which in turn reduces the spread of the virus. Clinical trials of remdesivir in COVID-19 patients are ongoing. Thus, the US National Institute of Health reported preliminary results showing that the time required for recovery of patients with coronavirus infection has decreased.
The researchers noted that it is important to know how remdesivir works because it is currently the only direct-acting antiviral drug currently approved for conditional or emergency use as treatment for COVID-19 in several countries, including Canada and the United States.
According to the authors of the work, remdesivir is a standard drug for combating COVID-19, the mechanism of which we need to know in order to further its effective use and create even more effective analogues.
Source: https://www.sciencedaily.com/releases/2020/09/200924082656.htm
